Literature DB >> 24509509

Stage-specific control of early B cell development by the transcription factor Ikaros.

Tanja A Schwickert1, Hiromi Tagoh1, Sinan Gültekin2, Aleksandar Dakic1, Elin Axelsson2, Martina Minnich2, Anja Ebert2, Barbara Werner2, Mareike Roth2, Luisa Cimmino3, Ross A Dickins3, Johannes Zuber2, Markus Jaritz2, Meinrad Busslinger2.   

Abstract

The transcription factor Ikaros is an essential regulator of lymphopoiesis. Here we studied its B cell-specific function by conditional inactivation of the gene encoding Ikaros (Ikzf1) in pro-B cells. B cell development was arrested at an aberrant 'pro-B cell' stage characterized by increased cell adhesion and loss of signaling via the pre-B cell signaling complex (pre-BCR). Ikaros activated genes encoding signal transducers of the pre-BCR and repressed genes involved in the downregulation of pre-BCR signaling and upregulation of the integrin signaling pathway. Unexpectedly, derepression of expression of the transcription factor Aiolos did not compensate for the loss of Ikaros in pro-B cells. Ikaros induced or suppressed active chromatin at regulatory elements of activated or repressed target genes. Notably, binding of Ikaros and expression of its target genes were dynamically regulated at distinct stages of early B lymphopoiesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24509509      PMCID: PMC5790181          DOI: 10.1038/ni.2828

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  66 in total

1.  High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP.

Authors:  C I Rodríguez; F Buchholz; J Galloway; R Sequerra; J Kasper; R Ayala; A F Stewart; S M Dymecki
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis.

Authors:  Thorsten Decker; Marina Pasca di Magliano; Shane McManus; Qiong Sun; Constanze Bonifer; Hiromi Tagoh; Meinrad Busslinger
Journal:  Immunity       Date:  2009-04-02       Impact factor: 31.745

3.  Aiolos regulates B cell activation and maturation to effector state.

Authors:  J H Wang; N Avitahl; A Cariappa; C Friedrich; T Ikeda; A Renold; K Andrikopoulos; L Liang; S Pillai; B A Morgan; K Georgopoulos
Journal:  Immunity       Date:  1998-10       Impact factor: 31.745

4.  Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations.

Authors:  A Dupuis; M P Gaub; M Legrain; B Drenou; L Mauvieux; P Lutz; R Herbrecht; S Chan; P Kastner
Journal:  Leukemia       Date:  2012-07-18       Impact factor: 11.528

5.  Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity.

Authors:  J Koipally; K Georgopoulos
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

6.  Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development.

Authors:  Shibin Ma; Simanta Pathak; Long Trinh; Runqing Lu
Journal:  Blood       Date:  2007-10-30       Impact factor: 22.113

7.  Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation.

Authors:  Isabel Ferreirós-Vidal; Thomas Carroll; Benjamin Taylor; Anna Terry; Ziwei Liang; Ludovica Bruno; Gopuraja Dharmalingam; Sanjay Khadayate; Bradley S Cobb; Stephen T Smale; Mikhail Spivakov; Prashant Srivastava; Enrico Petretto; Amanda G Fisher; Matthias Merkenschlager
Journal:  Blood       Date:  2013-01-09       Impact factor: 22.113

8.  Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic mice.

Authors:  Ernie de Boer; Patrick Rodriguez; Edgar Bonte; Jeroen Krijgsveld; Eleni Katsantoni; Albert Heck; Frank Grosveld; John Strouboulis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-11       Impact factor: 11.205

9.  The Rho-guanine nucleotide exchange factor Trio controls leukocyte transendothelial migration by promoting docking structure formation.

Authors:  Jos van Rijssel; Jeffrey Kroon; Mark Hoogenboezem; Floris P J van Alphen; Renske J de Jong; Elena Kostadinova; Dirk Geerts; Peter L Hordijk; Jaap D van Buul
Journal:  Mol Biol Cell       Date:  2012-06-13       Impact factor: 4.138

10.  Differential expression analysis for sequence count data.

Authors:  Simon Anders; Wolfgang Huber
Journal:  Genome Biol       Date:  2010-10-27       Impact factor: 13.583

View more
  98 in total

1.  RAG1 targeting in the genome is dominated by chromatin interactions mediated by the non-core regions of RAG1 and RAG2.

Authors:  Yaakov Maman; Grace Teng; Rashu Seth; Steven H Kleinstein; David G Schatz
Journal:  Nucleic Acids Res       Date:  2016-07-19       Impact factor: 16.971

Review 2.  Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Authors:  Markus Müschen
Journal:  Blood       Date:  2015-04-15       Impact factor: 22.113

3.  Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.

Authors:  J M Boer; A van der Veer; D Rizopoulos; M Fiocco; E Sonneveld; H A de Groot-Kruseman; R P Kuiper; P Hoogerbrugge; M Horstmann; M Zaliova; C Palmi; J Trka; E Fronkova; M Emerenciano; M do Socorro Pombo-de-Oliveira; W Mlynarski; T Szczepanski; K Nebral; A Attarbaschi; N Venn; R Sutton; C J Schwab; A Enshaei; A Vora; M Stanulla; M Schrappe; G Cazzaniga; V Conter; M Zimmermann; A V Moorman; R Pieters; M L den Boer
Journal:  Leukemia       Date:  2015-07-23       Impact factor: 11.528

4.  Transcription factor Hoxb5 reprograms B cells into functional T lymphocytes.

Authors:  Mengyun Zhang; Yong Dong; Fangxiao Hu; Dan Yang; Qianhao Zhao; Cui Lv; Ying Wang; Chengxiang Xia; Qitong Weng; Xiaofei Liu; Chen Li; Peiqing Zhou; Tongjie Wang; Yuxian Guan; Rongqun Guo; Lijuan Liu; Yang Geng; Hongling Wu; Juan Du; Zheng Hu; Sheng Xu; Jiekai Chen; Aibin He; Bing Liu; Demin Wang; Yong-Guang Yang; Jinyong Wang
Journal:  Nat Immunol       Date:  2018-02-12       Impact factor: 25.606

Review 5.  Mi-2/NuRD chromatin remodeling complexes regulate B and T-lymphocyte development and function.

Authors:  Carissa Dege; James Hagman
Journal:  Immunol Rev       Date:  2014-09       Impact factor: 12.988

6.  Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival.

Authors:  Jasmin Corso; Kuan-Ting Pan; Roland Walter; Carmen Doebele; Sebastian Mohr; Hanibal Bohnenberger; Philipp Ströbel; Christof Lenz; Mikolaj Slabicki; Jennifer Hüllein; Federico Comoglio; Michael A Rieger; Thorsten Zenz; Jürgen Wienands; Michael Engelke; Hubert Serve; Henning Urlaub; Thomas Oellerich
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-06       Impact factor: 11.205

7.  YY1 plays an essential role at all stages of B-cell differentiation.

Authors:  Eden Kleiman; Haiqun Jia; Salvatore Loguercio; Andrew I Su; Ann J Feeney
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-22       Impact factor: 11.205

Review 8.  Genomics in acute lymphoblastic leukaemia: insights and treatment implications.

Authors:  Kathryn G Roberts; Charles G Mullighan
Journal:  Nat Rev Clin Oncol       Date:  2015-03-17       Impact factor: 66.675

9.  IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK.

Authors:  Rossana Maffei; Stefania Fiorcari; Stefania Benatti; Claudio Giacinto Atene; Silvia Martinelli; Patrizia Zucchini; Leonardo Potenza; Mario Luppi; Roberto Marasca
Journal:  Leukemia       Date:  2021-02-23       Impact factor: 11.528

10.  Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.

Authors:  Iris Appelmann; Cory D Rillahan; Elisa de Stanchina; Gregory Carbonetti; Chong Chen; Scott W Lowe; Charles J Sherr
Journal:  Blood       Date:  2014-12-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.